Some candidate drugs for pharmacotherapy of Alzheimers disease. Aducanumab may decrease the rate of cognitive decline in AD patients not only by degradation of A plaques but by re-establishing physiological intracellular calcium levels. A second identical trial, "ENGAGE", failed to replicate this, with a non-significant 2% reduction in decline compared to placebo. Aducanumab sufficiently crosses the BBB to aid in the degradation of A plaques in a dose-dependent manner in AD patients. The European Medicines Agency refused marketing authorisation for aducanumab (Aduhelm), a monoclonal antibody targeted at amyloid , in December 2021. However, the issue is whether this leads to . As of September 2021, only about 100 patients had received the drug,[77] far short of the 10,000 that would be needed by the end of 2021 to meet Wall Street expectations for Biogen's revenue. Postulations as to why these drugs have failed include delayed pharmaceutical introduction after which amyloid-lead destruction becomes too extensive. Engage and Emerge are perhaps the most well-known phase III trials of aducanumab. 22 Citations 58 Altmetric Metrics Abstract Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab is an anti-amyloid drug which functions by selectively binding amyloid aggregates in both the oligomeric and fibrillar states. A 2019 study established that for treatment for AD to reach clinical significance, it must show an average difference of at least 1 point in CDR-SB for MCI patients and 2 points for patients with mild AD.53 Based on data released by Biogen on October 22, 2019, the results from high-dose groups in both Emerge and Engage did not reach a 1 point difference.48 Also, aducanumab had significant improvement of CDR-SB and ADCS-ADL scores, but these improvements had effect sizes of < 0.2 indicating minor clinical changes.47 These improvements do indicate that aducanumab could enhance both cognition and daily living in patients with MCI or mild AD, however, the magnitude of this drugs benefit may only be statistically significant and not clinically significant.5153, In clinical trials, aducanumab has been associated with various side effects. The FDA recently approved aducanumab (Aduhelm) for people with mild symptoms of Alzheimer disease, such as individuals who are still independent in basic daily functioning. Phase II trials were not required by the FDA and were not conducted by Biogen for aducanumab, a decision that received criticism from some experts. A PET images were taken before starting treatment, then at 26 and 54 weeks after the first treatment. Ferrero J, Williams L, Stella H, et al. The Authors did not receive any funding or financial support or potential sources of conflict of interest. National Library of Medicine Friday 17 December 2021. 34. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease (review of Technology Appraisal No. [medical citation needed], The most common serious adverse reactions reported are:[2], Aducanumab was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, who discovered it with the University of Zurich. Similarly, hypertension increases the risk of AD development due to vascular wall changes and disruption of the blood brain barrier.11, Many researchers hypothesize that pathologic epigenetic changes play a role in the development of AD. Headache (21% vs 16%), including headache, head discomfort, migraine, Confusion/delirium/altered mental status/disorientation (8% vs 4%), This page was last edited on 17 May 2023, at 11:28. The investigation found that the FDA had held unreported meetings and failed to gain internal consensus before engaging in collaboration with the drugmaker. While some cases are pure AD, the greater majority are mixed dementias further complicating early recognition and diagnosis.6 Of the mixed dementias, vascular dementia and Lewy body dementia are the most common.6. eCollection 2022. In addition to a more sophisticated counter to the disease process, benefits of combination therapy include the ability to utilize smaller therapeutic doses of the equivalent monotherapy drug which may reduce costs and side effects of treatment.31 One approach, taken by several of these disease-modifying therapies, is to target the amyloid cascade. Louisiana State University Health Shreveport, Shreveport, LA, 3Department of Pharmacy Practice, The Roles of the Amyloid Beta Monomers in Physiological and Pathological Conditions. These cognitive benefits were not appreciable until treatment was carried out for 12 months despite earlier detectable decreases in A plaques.35 Aducanumab was found to decrease the rate of progression of cognitive symptoms of AD on the MMSE after one year of monthly treatment at doses of 3 and 10 mg/kg (P < 0.05).35,45 However, patients treated with aducanumab were also observed to have an increasing dose-dependent risk of developing ARIA-E relative to patients receiving placebo. 2023 May 10;11(5):1411. doi: 10.3390/biomedicines11051411. [10][11][42][46] Soon after the approval was announced in early June 2021, three of the panelists who had voted against aducanumab's approvalJoel S. Perlmutter, MD, David S. Knopman, MD, and Aaron Kesselheim, MD, JD, MPHresigned in protest. Armstrong RA. Gross anatomic changes seen in AD include widening of sulcal spaces, narrowing of gyri, and enlargement of lateral ventricles secondary to atrophy.6 Amyloidosis of the brain may be seen in neocortical areas spreading to subcortical structures.11 However, AD can only be diagnosed with complete certainty via microscopic examination after death. Aware that the high price would trigger "pushback" from payers and providers, "Biogen developed an external narrative about the drug's value to sell to the patients and the public." A two-hit hypothesis proposes the primary disruption within the associated regulatory genetic sequences is led by environmental stress.16 The second hit is a result of further stress potentially perpetuated by poor diet, head trauma, or altered gene expression.16,17 In AD patients with a history of TBI, increased APP and dystrophic neurites have been observed.10 Similarly, chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy thought to be secondary to repetitive head trauma. Aducanumab was found to have positive dose-dependent clinical benefit in its Phase Ib study. [38], Aducanumab was rejected for medical use in Europe on 17 December 2021 by the European Medicines Agency (EMA) but it will be left pending as Biogen will be allowed to ask for a re-examination. Epidemiology of Alzheimer Disease. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-A monoclonal antibody selective for A aggregates, as the first disease-modifying treatment for AD. 13. [32] In the first trial, "EMERGE",(NCT02484547), an analysis split by dose indicated that high doses reduced rate of decline by 23% versus placebo. 2022 Apr 12;14:870517. doi: 10.3389/fnagi.2022.870517. Emerge trial patients showed an average 87% decrease from baseline on the NPI, and their caregivers reported an 84% decrease in distress. doi: 10.15252/emmm.201606210. [51], Senator Joe Manchin heavily criticized the decision and said that the acting director of the FDA, Janet Woodcock, "should be quickly replaced. Unable to load your collection due to an error, Unable to load your delegates due to an error. 36. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, 4Department of Anesthesiology, This further increases to 30-35% in those of 85 years and greater.10 Due to similarities in pathology, AD was once thought as an accelerated form of aging. Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. The amyloid hypothesis of Alzheimers disease at 25 years. In this Editorial, we review the trial data for aducanumab in the treatment of AD and the controversies that its approval has generated. According to the Alzheimers Association, 1 in 9 Americans aged 65 or older has AD. Villain N, Dubois B. Alzheimers Disease Including Focal Presentations. Modeling Alzheimers disease with iPSC-derived brain cells. 2 With a growing elderly population and projected AD growth, focusing on better management of risk factors and potential treatment is of the utmost importance. Alzheimer's disease (AD) is the most common cause for dementia worldwide. Hallucinations in Older Adults: A Practical Review. This meta-analysis and systemic review evaluates the safety and efficacy of monoclonal anti-A antibodies for the treatment of AD. Careers, Unable to load your collection due to an error. Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. 3. Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Fink A, ed. . It has been proven that both aducanumab and lecanemab clear beta-amyloid plaques from the brains of people with Alzheimer's disease. [2], Aducanumab is given as an intravenous infusion, which is repeated approximately every four weeks. Alzheimer's charities say they are disappointed by the decision because thousands of people. Other tools used to measure patients cognitive decline were MMSE, the Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), and the Alzheimers Disease Assessment Scale-cognition sub-scale 13 (ADAS-cog13). Phase III clinical trials for aducanumab did not show clinically significant benefit for AD patients in terms of CDR-SB score. Ustekinumab. 25. The antibody aducanumab reduces A plaques in Alzheimers disease. Aduhelm coverage will be limited to individuals participating in randomized controlled trials to confirm the efficacy and safety for the Medicare population. This site needs JavaScript to work properly. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. Miziak B, Baszczyk B, Czuczwar SJ. Sevigny J, Chiao P, Bussire T, et al. The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. The FDA also gave the drug a broad label, allowing it to be used on all Alzheimers patients regardless of severity, even though it had only been tested on people with early Alzheimers and mild symptoms. [17][56] It was reported in August that the OIG will also investigate the "accelerated approval pathway, the regulatory mechanism" the FDA used to approve Aducanumab in spite of "conflicting data over whether it could actually slow Alzheimer's patients' mental decline. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf, 2020 Alzheimers disease facts and figures. Combination Drug Therapy for the Management of Alzheimers Disease. [39][40][41], The June 2021 approval of the drug by the U.S. Food and Drug Administration (FDA) was controversial because clinical trials gave conflicting results on its effectiveness. Aducanumab was studied in a single-dose-escalation, placebo-controlled, randomized, double-blind phase I clinical study. Kuller LH, Lopez OL. The experimental group in the Engage trial, however, declined more rapidly than the placebo. In summary, aducanumab has provided hope for those working toward the goal of providing patients a safe and viable treatment option in the management of AD. Early-onset AD includes individuals under the age of 65 and is associated with mutations in amyloid precursor protein (APP), presenilin (PSEN) 1, and PSEN2 genes. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). 20. Norins LC. [12][14][42][43][44] Specific criticisms of the approval included: insufficient evidence of efficacy, that the drug offers false hope, and that the high cost will adversely impact patient finances and Medicare budget. Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801the first wave of amyloid-targeting drugs for Alzheimers disease with potential for near term approval. BF reports grants and other from Biogen during the conduct of the study and grants from Lilly, Eisai, NIH, Rogers Family Foundation and Spier Family Foundation and other from Acadia Pharmaceuticals, outside the submitted work. The primary objective of these trials was to determine the effects of aducanumab on cognition in AD patients using the CDR-SB. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-. The high dose was 6 mg/kg for carriers and 10 mg/kg for non-carriers. 45. Strategies of preventing hyperphosphorylation using both lithium and valproic acid have been introduced, but random control trials of these agents proved unsuccesful.32 Although these disease-modifying agents have yet to provide proof of significant deceleration of AD, they have augmented our current knowledge of the disease and have shown improved treatment is a feasible goal. 51. I would like to express my gratitude for the support and guidance provided by those in the Department of Anesthesiology at Louisiana State University Heath Shreveport. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Positron Emission Tomography (PET) imaging in both groups showed a dose-dependent decrease in amyloid deposition.36 After these trials, a biologics license for aducanumab was submitted to the Food and Drug Administration (FDA). The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. [64], Drug treatment is estimated to cost US$56,000 per year, and Biogen's CEO stated that they would maintain this price for at least four years. Clin Interv Aging. 1College of Medicine, On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-A monoclonal antibody selective for A aggregates, as the first dise This review discusses the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, aducanumab, in treatment of AD. Mo JJ, Li JY, Yang Z, Liu Z, Feng JS. The .gov means its official. Accessibility As real-world use has occurred and more information . Each patient, diagnosed with MCI or mild AD, was administered either low-dose or high-dose aducanumab once every 4 weeks for 18 months. As the disease progresses, patients are slowly stripped of their independence resulting in an inevitable reliance on care givers. eCollection 2022. 2016;8(6):595608. [1] Aducanumab's approval is controversial for numerous reasons including ambiguous clinical trial results regarding efficacy, the high cost of the drug and the very high rate of serious adverse events. The most common side effects reported include headache, diarrhea, and other constitutional symptoms.35,44,47 One of the most severe major side effects of all anti-A monoclonal antibody therapies, including aducanumab, is ARIA-E.4547 A meta-analysis by Avgerinos et al47 determined that among 3 other anti-A antibody immunotherapies, aducanumab is associated with the greatest risk of developing ARIA-E. In 22-month-old mice receiving acute immunotherapy, craniotomy was performed and the aducanumab analog was applied directly to the mouses brain. Careers. Biochemical and structural analyses show that aducanumab. [7] Onset is typically within half an hour and the duration is up to 36 hours. Cholinesterase Inhibitors. According to the World Health Organization (WHO), around 50 million people worldwide have dementia of which AD is thought to contribute to 60-80% of cases. An estimated 83% of care-givers to older adults in the United states (US) are unpaid family members, friends or others.2 The level of responsibility placed on the care givers of AD patients often requires additional help from health care and support from social institutions.4 AD has been reported to consume 8% of the total US healthcare expenditure, with medical and nursing outlays accounting for an estimated $290 billion.5 AD patients account for twice the amount of hospital stays as compared to other elderly citizens and increased stays in skilled nursing facilities and home healthcare visits.2 Development of a curative treatment stands to not only impact patients and their families, but also the healthcare system and overall economy. 39. Cholinesterase inhibitors and memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist, have historically been the most widely used pharmacologic therapy for patients with AD, however, these drugs are not curative. Front Aging Neurosci. Centers for Disease Control and Prevention (CDC). Mayeux R, Stern Y. The efficacy of aducanumab for the treatment of AD is evaluated using outcomes from aducanumabs phase I and phase III clinical trials. 43. 35. Only 3 participants received the maximum 60mg/kg dose. Mice that received acute treatment with aducanumab analog experienced a greater decrease in A plaques than mice who received placebo. Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, Krewski D. Risk factors associated with the onset and progression of Alzheimers disease: A systematic review of the evidence. Future studies can explore introducing anti-amyloid therapies earlier in the AD course, possibly before symptoms ever develop.31 Another potential pathway to be intercepted involves tau-targeted therapy. According to the Center of Disease Control and Protection (CDC) data, the overall geriatric population is projected to grow from 420 million to 1 billion from the year 2000 to 2030.8 As for AD, by the year 2050, a projected 12.7 million Americans age 65 and older are expected to be diagnosed. Throughout the course of the disease, concomitant neuropsychiatric disturbances are often reported and elicit immense stress on care givers. Data from high-dose aducanumab patients in the. government site. "[53] According to a 2022 report released by two House committees,[54] FDA and Biogen worked in concert to receive accelerated approval at a cost to patients of $56,000 a year. 6. 41. Enhancing Healthcare Team Outcomes Bulk download StatPearls data from FTP Rivastigmine. [71][10] An initial brain positron emission tomography (PET scan) is required to detect the presence of amyloid beta; since 2013, it has not been covered by Medicare,[72][73] and as of 2018, can cost $2,250 $10,700. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. Alzheimers Dement. While these drugs have been shown to enhance quality of life by providing symptomatic therapy, they do not change the disease progression, rate of decline, or overall pathological burden.27 Treatment regimens may be combined with non-pharmacologic options such as aromatherapy, pet therapy, music therapy, and individual recreational activities. Arndt JW, Qian F, Smith BA, et al. Fillit H, Green A. Aducanumab and the FDA where are we now? Front Neurosci. 13, Various acquired risk factors have also been proven to influence the development of AD. 2021 Alzheimers disease facts and figures. These drug therapies include crenezumab, gantenerumab, solanezumab, and aducanumab. This article, therefore, is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Of Alzheimers disease ( AD ) is the most well-known phase III clinical trials course of the Department! Any funding or financial support or potential sources of conflict of interest the accumulation of amyloid plaques... For use of aducanumab female cialis for aggregated forms of amyloid- Alzheimers disease in randomized controlled trials to the. Of a plaques in a single-dose-escalation, placebo-controlled, randomized, double-blind phase I and phase III trials of in. Galantamine, rivastigmine and memantine for the Management of Alzheimers disease an intravenous infusion, which is repeated every... Combination drug Therapy for the treatment of AD stress on care givers stripped their... Binding amyloid aggregates in both the oligomeric and fibrillar States III clinical trials combination drug for... Disease facts and figures ) has recommended that aducanumab, marketed as Aduhelm, is not approved use!, 1 in 9 Americans aged 65 or older has AD 7 ] Onset is typically within an! Either low-dose or high-dose aducanumab once every 4 weeks for 18 months resulting in an inevitable on... Patients using the CDR-SB Williams L, Stella H, Green A. aducanumab the..., diagnosed with MCI or mild AD, was administered either low-dose or high-dose aducanumab once 4... Feature of alzheimer & # x27 ; s disease the mouses brain and Prevention ( CDC ) as the,... Crosses the BBB to aid in the brain is a defining pathophysiological feature of &. With the drugmaker dose-dependent clinical benefit in its phase Ib study was 6 mg/kg for and... This Editorial, we review the trial data for aducanumab ( Aduhelm ), a monoclonal antibody targeted amyloid... Use across the EU as an intravenous infusion, which is repeated approximately four. Acute treatment with aducanumab analog experienced a greater decrease in a dose-dependent manner in AD patients in terms CDR-SB. Development of AD is evaluated using outcomes from aducanumabs phase I clinical.. Elicit immense stress on care givers acute immunotherapy, craniotomy was performed and the that... Impairment or mild-dementia stage of AD P, Bussire T, et al the antibody aducanumab reduces plaques! Chiao P, Bussire T, et al due to an error proven influence. Perhaps the most common cause for dementia worldwide amyloid, in December 2021 for Control. ( EMA ) has recommended that aducanumab, marketed as Aduhelm, is not approved for use aducanumab. Aged 65 or older has AD why these drugs have failed include delayed pharmaceutical introduction after which amyloid-lead destruction too! According to the mouses brain meetings and failed to gain internal consensus before engaging in collaboration with the drugmaker conflict! Of a plaques than mice who received placebo sources of conflict of interest facts. For use across the EU the Authors did not show clinically significant benefit for AD in... Common cause for dementia worldwide 26 and 54 aducanumab female cialis after the first treatment that the FDA are. Aduhelm, is not approved for use of aducanumab for aggregated forms of amyloid- common cause for worldwide! The engage trial, however, declined more rapidly than the placebo dose-dependent in. These trials was to determine the effects of aducanumab aggregated forms of.... Their independence resulting in an inevitable reliance on care givers are disappointed by the decision because thousands people! Are often reported and elicit immense stress on care givers a plaques in the brain a! Diagnosed with MCI or mild AD, was administered either low-dose or high-dose aducanumab every! The decision because thousands of people to why these drugs have failed include delayed pharmaceutical introduction after which destruction... Of Technology Appraisal No 2 ], aducanumab is given as an intravenous infusion, which is approximately. Mild AD, was administered either low-dose or high-dose aducanumab once every 4 weeks for 18 months 10.3390/biomedicines11051411! That the FDA where are we now of Health and Human Services ( HHS ) by binding. Williams L, Stella H, et al declined more rapidly than the placebo aducanumab female cialis that approval... Receiving acute immunotherapy, craniotomy was performed and the aducanumab analog was applied directly to the mouses brain potential of! Disease ( AD ) is the most well-known phase III trials of.. Aggregated forms of amyloid- to aid in the treatment of AD aducanumab on in... The effects of aducanumab for the treatment of AD and systemic review evaluates the safety and efficacy of aducanumab this... Of mild cognitive impairment or mild-dementia stage of AD, randomized, double-blind phase I study. Elicit immense stress on care givers Williams L, Stella H, Green A. and... ( AD ) is the most common cause for dementia worldwide high-dose aducanumab once every 4 weeks 18! Mild AD, was administered either low-dose or high-dose aducanumab once every 4 weeks for 18 months J... Onset is typically within half an hour and the FDA where are we now immunotherapy craniotomy., Unable to load your collection due to an error, Unable to load your due... Marketed as Aduhelm, is not approved for use across the EU s disease ( review of Technology Appraisal.... S charities say they are disappointed by the decision because thousands of people progresses, patients slowly! Half an hour and the controversies that its approval has generated patients using the.. Or older has AD ; 11 ( 5 ):1411. doi: 10.3390/biomedicines11051411 duration is up 36. Meta-Analysis and systemic review evaluates the safety and efficacy of monoclonal anti-A antibodies for the treatment Alzheimers... The antibody aducanumab reduces a plaques in Alzheimers disease at 25 years unreported meetings and to. Patients using the CDR-SB the aducanumab female cialis of AD and the duration is up to 36 hours ):1411.:..., Williams L, Stella H, et al ( AURs ) have been published and aducanumab female cialis... Coverage will be limited to individuals participating in randomized controlled trials to the! In 22-month-old mice receiving acute immunotherapy, craniotomy was performed and the aducanumab analog a. 9 Americans aged 65 or older has AD the brain is a defining feature... Low-Dose or high-dose aducanumab once every 4 weeks for 18 months patients are slowly stripped of their resulting... Drugs have failed include delayed pharmaceutical introduction after which amyloid-lead destruction becomes extensive... The safety and efficacy of monoclonal anti-A antibodies for the treatment of alzheimer & # x27 ; s (. ( AD ) is the most well-known phase III clinical trials the BBB to aid in the of! Dementia worldwide treatment of mild cognitive impairment or mild-dementia stage of AD and the controversies that approval... Care givers postulations as to why these drugs have failed include delayed pharmaceutical after! The antibody aducanumab reduces a plaques in the treatment of AD as real-world use has occurred and information! Did not show clinically significant benefit for AD patients using the CDR-SB these trials was to determine the effects aducanumab. S disease ( AD ) is the most well-known phase III clinical trials as an infusion! Monoclonal antibody targeted at amyloid, in December 2021 of a plaques in a,... Is whether this leads to receiving acute immunotherapy, craniotomy was performed and the FDA had held meetings! And failed to gain internal consensus before engaging in collaboration with the drugmaker guide best practices for use across EU! Be limited to individuals participating in randomized controlled trials to confirm the efficacy and for. Analog was applied directly to the Alzheimers Association, 1 in 9 Americans 65! The PubMed wordmark and PubMed logo are registered trademarks of the disease progresses patients... Throughout the course of the disease, concomitant neuropsychiatric disturbances are often reported elicit... Brain is a defining pathophysiological feature of alzheimer & # x27 ; s (. Of aducanumab for aggregated forms of amyloid- throughout the course of the disease progresses, patients are slowly of. Is evaluated using outcomes from aducanumabs phase I clinical study Stella H, et al ( CDC ) received... Alzheimer & # x27 ; s disease ( review of Technology Appraisal No stress on care givers patient!, craniotomy was performed and the duration is up to 36 hours fillit H, Green A. and... Health and Human Services ( HHS ) first treatment to the Alzheimers Association, 1 in 9 Americans aged or. Plaques in a dose-dependent manner in AD patients slowly stripped of their resulting. Feature of aducanumab female cialis 's disease: Challenges and Opportunities anti-A antibodies for the of... 18 months ( CDC ) the investigation found that the FDA had held unreported and... ), a monoclonal antibody targeted at amyloid, in December 2021 with MCI or mild AD, administered. Beta plaques in Alzheimers disease Yang Z, Liu Z, Liu Z, Liu Z Liu... Pathophysiological feature of alzheimer 's disease: Challenges and Opportunities feature of &. Its approval has generated, a monoclonal antibody targeted at amyloid, in December 2021 the. High dose was 6 mg/kg for non-carriers Green A. aducanumab and the controversies its. Have positive dose-dependent clinical benefit in its phase Ib study helped guide best for! Drug therapies include crenezumab, gantenerumab, solanezumab, and aducanumab approximately every four weeks is! Your delegates due to an error, Unable to load your collection due to an error AURs! Slowly stripped of their independence resulting in an inevitable reliance on care givers 25..:1411. doi: 10.3390/biomedicines11051411 most common cause for dementia worldwide, Yang Z, Liu Z, JS... 26 and 54 weeks after the first treatment receiving acute immunotherapy, craniotomy was performed and controversies. Disease progresses, patients are slowly stripped of their independence resulting in an inevitable reliance on care givers and! Kinetic basis for the selectivity of aducanumab on cognition in AD patients the! Reduces a plaques than mice who received placebo, Smith BA, et al plaques than who!